European Primary Care Cardiovascular Society

First-in-human study with CRISPR/Cas9-based gene editing in transthyretin amyloidosis with cardiomyopathy

3' education - Nov. 6, 2022 - Prof. Julian D. Gillmore, MD, PhD - London, UK

Educational information

This video was recorded during the AHA Scientific Sessions 2022 in Chicago, IL, USA.

Faculty

Prof. Julian D. Gillmore, MD, PhD - London, UK

Disclosures

This recording was developed under auspices of EPCCS. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of EPCCS.

Read our summary of this study

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: